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doi:10.1016/j.jtcvs.2008.02.069Objectives: The propensity of malignant pleural mesothelioma to metastasize to N1 or
N2 nodes and their corresponding prognostic value is unclear. The American Joint
Committee on Cancer staging system groups N1 and N2 disease together as stage
III. The goal of this study was to define the prognostic value of specific nodal stations.
Methods: Patientswithmalignant pleuralmesotheliomawhounderwent resectionwere
identified from an institutional database. Nodal stations were defined by the American
Joint Committee onCancer lung cancer nodemap classification. Survivalwas analyzed
by the Kaplan–Meier method, log-rank test, and Cox proportional hazards analysis.
Results: From 1990 to 2006, 348 patients were identified: 279 men and 69 women
with a median age of 67 years (range 26–85 years). Extrapleural pneumonectomy
was performed in 223 cases, and pleurectomy/decortication was performed in 125
cases. Survival differences (P , .01) were observed between 2 groups: N0 or
N1(1) (median survival 5 19 months) and N2(1), N2/N1(1) and internal
thoracic(1) (median survival 5 10 months). Survival was influenced by the number
of involved N2 stations (0, 1, 2, or more: P, .001). Multivariate analysis grouping all
N2 and internal thoracic(1) versus N1(1) and N0 demonstrated a hazard ratio for sur-
vival of 1.7 (P , .0001) controlling for T3/T4 status (hazard ratio 5 1.3, P , .01),
non-epithelioid histology (hazard ratio 5 1.7, P , .0001), extrapleural pneumonec-
tomy (1.1, P 5 .4), and male gender (hazard ratio 1.4, P , .01).
Conclusion: This study confirms a preferential pattern of drainage of malignant pleu-
ral mesothelioma to N2 rather than N1 lymph nodes, but suggests that N1 only nodal
involvement should be classified as lower stage disease. Multiple N2 nodal site in-
volvement could potentially be classified as higher stage disease than single station
N2. Our results emphasize the need for larger, confirmatory multicenter studies that
could lead to revision of the current staging system.
T
he current staging system for malignant pleural mesothelioma (MPM), pro-
posed in 1995 by the International Mesothelioma Interest Group, is based
on information about the relationships between T and N status and overall sur-
vival.1-7 The staging system has been validated by several reports8-12 and accepted by
the Union Internationale Contre le Cancer and American Joint Commission on Cancer
(AJCC) as the standard system for MPM. However, it was understood at its inception
that revision would be necessary as more data became available.13 Although previous
staging systems have suggested separating N1 from N2 nodes, there have been little
data to support this distinction. Data are also sparse regarding the influence of internal
thoracic nodes on survival.14
The lymph node map for MPM is by default the same used by the AJCC for lung
cancer staging.15 However, the lymphatic drainage from the lung is thought to beThe Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 3 605
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TSAbbreviations and Acronyms
AJCC 5 American Joint Commission on Cancer
EPP 5 extrapleural pneumonectomy
HR 5 hazard ratio
P/D 5 pleurectomy/decortication
MPM 5 malignant pleural mesothelioma
different from that of the pleura, and this may lead to different
patterns of lymph node involvement.9 It is conceivable that
N1 nodes could even represent more advanced disease and
portend a worse prognosis than N2 nodes in MPM if N2
nodes are actually the first site of drainage from the pleura.
The current AJCC staging system groups N1 and N2 disease
together as stage III because few data were available on the
relative impact of these sites of lymph node involvement
when the staging system was developed. The goal of this
study was to provide more data regarding the prognostic
impact of specific nodal groups, in particular N1 nodes.
Materials and Methods
Acquisition of Clinical Data
After approval from the institutional review board of Memorial
Sloan-Kettering Cancer Center, all patients with biopsy-proven
MPM who underwent surgical resection with complete mediastinal
nodal dissection or sampling from 1990 to 2005 at Memorial Sloan-
Kettering Cancer Center were identified from the thoracic surgery
database. Patients who had incomplete nodal staging information
were excluded from this study. Pathological diagnosis was based
on histology, immunohistochemical analysis, and, when indicated,
electron microscopy. Staging was performed using the sixth edition
of the AJCC Cancer Staging Handbook.1 Pathological stage was
based on the pathologist’s evaluation of the resected specimen and
the surgeon’s intraoperative findings. Dates of death were verified
through the Social Security Death Index.
Surgical and Multimodality Management
Operative intervention was recommended to patients with tumor
localized to the hemithorax by computed tomography scan and
adequate cardiopulmonary function determined by cardiac stress
testing and pulmonary function testing. Routine mediastinoscopy
was not performed. Extrapleural pneumonectomy (EPP) was de-
fined as an en bloc resection of the pleura, lung, ipsilateral dia-
phragm, and pericardium. Pleurectomy/decortication (P/D), which
removed all gross tumor without removing underlying lung, was
performed in patients who had minimal visceral pleural tumor or
poor pulmonary function. The decision to perform an EPP was pri-
marily based on intraoperative findings of confluent visceral tumor
not separable from the underlying lung and a partially or totally
fused pleural space. Lymph node sampling or dissection was per-
formed in the same manner as would be standard for a lung cancer
resection, including lymph node stations 2R, 4R, 7, 8, and 9 on the
right, and 5, 6, 7, 8, 9 for left-sided resections.15 The decision to
administer chemotherapy or radiation was based on the require-
ments of sequential clinical trials performed during this time period.606 The Journal of Thoracic and Cardiovascular Surgery c SepWhen the patient could not participate in a clinical trial, treatment
was usually administered according to protocol guidelines.
Statistical Methods
Operative mortality included all patients who died within 30 days of
surgery or during the same hospitalization. Survival was calculated
from the date of surgery until the date of death or date of last follow-
up. Survival according to nodal station involvement (N1 vs N2) was
analyzed by the Kaplan–Meier method. The log-rank test was used
to assess the statistical significance of potential prognostic factors. A
Cox proportional hazard analysis was used to assess the joint influ-
ences of known predictors on survival by nodal station. Insignificant
variables were then dropped using a stepwise procedure, thus yield-
ing the final model. The STATA 8 (StataCorp, College Station, Tex)
statistical package was used.
Results
From 1990 to 2006, 348 patients were identified as appropri-
ate for analysis. Patient characteristics are outlined in Table 1.
As is typical for MPM, most patients were male and had ep-
ithelioid tumors and stage II or III disease at diagnosis. With
a median follow-up of 20months, the median overall survival
for all 348 patients was 15 months, and the 5-year survival
was 13%. Tumor histologic subtype and AJCC stage strati-
fied patients by survival. EPP was performed in 223 patients,
and P/D was performed in 125 patients, with a mortality of
2% (n 5 5/223) for EPP and 2% (n 5 3/125) for P/D. There
were no significant differences in survival according to the
surgical procedure performed (P 5 .78). The distribution of
positive nodal stations for right and left-sided resections is
shown in Figure 1, A and B. The most frequently involved
lymph node stations were 4R, 7, and 10R for right-sided
tumors and 5, 7, and 10L for left-sided tumors.
TABLE 1. Clinical and treatment characteristics of the 348
patients in the study
n (%)
Male 279 (80%)
Histology
Epithelioid 257 (74%)
Non-epithelioid 91 (26%)
Stage
I 20 (6%)
II 83 (24%)
III 210 (60%)
IV 35 (10%)
Operation
EPP 222 (64%)
P/D 126 (36%)
Adjuvant therapy
Chemotherapy 38 (11%)
Radiotherapy 128 (37%)
Both 65 (19%)
EPP, Extrapleural pneumonectomy; P/D, pleurectomy/decortication.tember 2008
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TSDifferences in overall survival were observed between
patients who were N0 or N1 positive (median survival of
19 months) and those who were N2 positive, N2/N1 positive,
and internal thoracic node positive (median survival of 10
months) (Table 2; Figure 2). Survivals by solitary N2 versus
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Figure 1. A, Distribution of positive node stations: left lung. Most
patients who had lymph node metastases had more than 1 nodal
station involved, so the number of metastatic sites exceeds the
number of resections. B, Distribution of positive node stations:
right lung. Most patients who had lymph node metastases had
more than 1 nodal station involved, so the number of metastatic
sites exceeds the number of resections.
TABLE 2. Table by positive and negative nodal groups (24
patientswithpositive internal thoracicnodesarenot included)
N21 N2- Total
N11 65 22 87
N1- 45 192 237
Total 110 214 324The Journal of Thorsolitary N1 disease, number of involved nodal stations, and
N1/N2 positive versus N2 only positive are shown in Figures
3, 4, 5, and 6, respectively. When N2 disease was present,
survival was not significantly different whether or not N1 dis-
ease was also present. Of note, there were differences in sur-
vival according to the number of involved N2 nodal stations
with a significantly worse survival when 2 or more stations
had metastatic disease. Survivals by grouping levels 4 and
7 versus 8 and 9 versus 5 and 6 were no different (P 5 .36).
Only 10 patients who underwent P/D had complete N1
nodal dissection, of whom only 1 patient had a positive N1
node only, 5 patients had positive N1 and N2 nodes, and 4
patients had documented negative N1 nodes. The N2 only
and internal thoracic node positive patients (n 5 31) were
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Figure 2. Overall survival of patients with N0, N1(1) versus
N2(1), N2/N1(1) and internal thoracic(1) nodal disease.
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Figure 3. Overall survival of patients with N1 only versus N2 only
nodal disease.acic and Cardiovascular Surgery c Volume 136, Number 3 607
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TSpresumed to have negative N1 disease for the purpose of this
analysis. Therefore, the same analysis in Figures 1, 2, and 4
was performed exclusively in patients undergoing EPP with-
out demonstrating any change in the final results.
A Cox proportional hazards model grouping all N2 and
thoracic positive nodes versus N1 positive and N0 nodal sta-
tions demonstrated a hazard ratio (HR) of 1.6 (P , .0001)
controlling for T3/T4 status (HR5 1.3, P, .01), non-epithe-
lioid histology (HR 5 1.7, P , .0001), EPP (1.1, P 5 .42),
and male gender (HR 1.4, P 5 .01) (Table 3). Surgical pro-
cedure was not significant in the multivariate analysis. The
presence of metastasis to nodal areas by histology was not
statistically significant by logistic regression, most likely be-
cause of the low number of patients with sarcomatoid carci-
noma (n 5 19).
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Figure 4. Overall survival of patients with N1/N2 versus N2 only
nodal metastases.
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Figure 5. Overall survival of patients with 0, 1, and 2 or more nodal
stations involved.608 The Journal of Thoracic and Cardiovascular Surgery c SepDiscussion
The current AJCC staging system was built on previous stag-
ing systems but incorporated specific TNM descriptors based
on emerging information about their influence on survival.13
The purpose of the staging system was to describe the ana-
tomic extent of disease and group staged subsets by survival,
but as with other solid tumor staging systems, it does not take
into account tumor biology. It was understood at its inception
that revision of the staging system might be appropriate as
additional data about the influence of nodal involvement on
survival became available.
Little is known about the lymph node drainage pattern of
the parietal pleura. Studies from rat and pig experiments sug-
gest preferential drainage to the superior mediastinum.16,17
However, to our knowledge the patterns of lymphatic drain-
age from the pleura have not been determined in live humans.
Cadaveric studies have shown diaphragmatic pleural drain-
age to the peritracheobronchial lymph nodes via the pulmo-
nary ligament and periesophageal tissue.18 MPM provides
a unique clinical scenario from which to gain insight into
the pleural nodal drainage patterns in humans.
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Figure 6. Overall survival of patients by T stage.
TABLE 3. Multivariate analysis of prognostic factors and
overall survival
HR CI P value
EPP 1.1 (0.87–1.4) .42
Non-epithelioid histology 1.7 (1.3–2.2) ,.0001
T stage III/IV 1.3 (1.1–1.7) ,.01
Male gender 1.4 (1.1–1.9) ,.01
All N2 and ITA(1) nodes 1.6 (1.3–2.0) ,.0001
HR, Hazard ratio; CI, confidence interval; EPP, extrapleural pneumonectomy;
ITA, internal thoracic artery.tember 2008
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TSThis study demonstrates the expected characteristics of
any MPM cohort: a predominance of male patients, epitheli-
oid histology, and later stage, confirming the adverse impact
of N2 disease on overall survival.11,14 This study also con-
firms our previous data in a smaller number of patients show-
ing that MPM has a greater propensity to metastasize to N2
nodes than N1 nodes, and that nodal involvement is common,
occurring in approximately half of patients at surgery.11
Similar percentages of nodal involvement have been reported
in other studies by Edwards and colleagues,19 Pass and
colleagues,9 de Perrot and colleagues,20 and Aziz and col-
leagues,21 exceeding the 25% reported by Sugarbaker and
colleagues.14 Our data emphasize the importance of perform-
ing both N1 and N2 nodal dissections in patients undergoing
P/D to ensure complete staging.
Solitary metastasis to N1 nodes demonstrated a trend to-
ward improved survival when compared with solitary metas-
tasis to N2 nodes, thus implying earlier stage disease. In
addition, further evidence for separating N1 disease from
N2 disease in the staging system is provided by our data
showing no further decline in survival in N2/N1 positive pa-
tients when compared with patients with solitary N2 disease.
Because we demonstrated significantly worse survival for
patients with 2 or more positive N2 nodal stations, one would
expect survival for the N2/N1 positive (or 2 station nodal
disease) patients to be worse than that of the patients with
solitary N2. However, the survival was no different, thus sup-
porting a recommendation that N1 be staged differently from
N2 disease.
The internal thoracic lymph nodes have been included as
N2 disease in the current staging system based on hypothet-
ical reasoning rather than data. Our data confirm that internal
thoracic lymph nodes can be appropriately considered N2,
stage III disease. There were also no survival differences
observed according to involvement of nodal stations 4, 5,
6, 7, 8, and 9. Therefore, it is appropriate to classify all these
nodal stations as N2 disease and stage III.
A salient result from our study is the adverse impact of
multiple versus single N2 lymph node stations on survival.
This finding corroborates our previous data suggesting that
the number of involved lymph nodes influences survival.11
Because the counting of lymph nodes is potentially unreliable
because of the difficulty for pathologists in identifying nodal
fragments from entire nodes in surgical specimens, the num-
ber of involved lymph node stations is a more reproducible
data point for universally acceptable staging.
Trials investigating induction chemotherapy have sparked
increased interest in pre-resectional nodal staging.22,23 Al-
though the routine use of invasive preoperative nodal staging
is controversial, newer preoperative staging modalities, such
as endobronchial ultrasound to identify N1 disease and
esophageal ultrasound to identify N2 disease at levels 8
and 9, may prove useful in clinical trials as more effective
chemotherapy becomes available.20,24-27The Journal of ThorConclusions
This study confirms a preferential pattern of drainage of
MPM to N2 rather than N1 lymph nodes, but suggests that
N1 only nodal involvement should be classified as lower
stage disease. Multiple N2 nodal site involvement could
potentially be classified as higher stage disease than single
station N2. Our results emphasize the need for larger, confir-
matory multicenter studies that could lead to revision of the
Union Internationale Contre le Cancer and AJCC staging
systems.
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Discussion
Dr. W.R. Smythe (Temple, Texas): Drs. Wright and Jones, mem-
bers, and guests:
Thanks for the opportunity to discuss this paper.
Pierre Denoix was a French pathologist who did the initial work
on the TNM staging system in the early 1940s. He was at the Na-
tional Institute of Hygiene there. What you may not know, actually,
is that not only do we have New York to thank for this group and all
of their contributions to thoracic surgery, but we also have New
York to thank for the TNM staging system in general, as the Na-
tional Institute of Hygiene was funded by the Rockefeller Founda-
tion of New York, allowing
Dr. Denoix to do his work.
It seems amazing to me that we have resisted for such a long time
the notion that mesothelioma is any different from any other tumor.
There are idiosyncrasies of this disease, but certainly tumor extent,
histologic type, and nodal status are just as important as they are for
breast cancer and for lung cancer, and that really shouldn’t come as
a surprise to us.
This work is really a continuation of the work been that has been
done by Dr. Rusch and her colleagues since the mid-1990s, and I
think now we have unequivocal proof that the TNM staging system
for this disease is useful and should be adhered to. And, as Dr. Gins-
berg said in 1995 when I was a fellow listening to Dr. Rusch make
one of the first presentations about this concept at this meeting that
we had 7 or 8 staging systems, we really should have one. I think that610 The Journal of Thoracic and Cardiovascular Surgery c Septhe proof is in the pudding now. The pudding is done. It’s time for us
just to have one staging system, and we appreciate your efforts.
I just have three questions. First, in considering the importance of
the sarcomatous histologic subtype in this disease, did you see any
difference in the metastatic patterns for sarcomatous versus epithe-
lial to the nodal stations, and if you did, are there any implications
for the staging system in regards to histologic type, knowing how
badly those patients do?
The second question is, if you’re suggesting that we should stage
patients at the N1 level, how do we do that? These lungs are often
encased in tumor. How do we convince our pathology colleagues
actually to dissect these nodes out of these lungs that are so heavily
encased with disease in the fissure, disease that often travels up the
bronchus into the hilum?
Lastly, now that we know the importance of N2 disease, and,
again, it has been shown by many groups, including yours and
ours in Texas and so forth, how do we clinically stage these patients
for N2 disease, especially in locations that are extratracheal loca-
tions, like levels 8, 9, and the internal mammary chain? I think there
were 79 patients in your study that had disease in these areas. If you
only have disease in these areas, how do you clinically stage the pa-
tients before surgery? The tumor oftentimes is adjacent to the nodes.
It’s difficult to discern the node from the tumor in regards to PET
scanning. And in our experience in Texas, we found that regardless
of nodal size, even a 3 mm lymph node at levels 8, 9, and the internal
mammary chain can harbor tumor. How do we clinically stage these
patients and make good decisions about who to operate on and who
not to operate on in regards to their stage?
Again, thanks for the opportunity. It was a great paper. Thanks
for giving me the paper ahead of time. It was very well written, suc-
cinct, and clear. I appreciate it.
Dr. Flores: With regard to the first question about the differences
in nodal spread based on histology, we have found a decent amount
of nodal disease in patients who have had sarcomatoid and mixed
tumors. However, the numbers of sarcomatoid patients are very,
very small. The mixed tumors tend to spread to the nodal stations
in a similar way as the epithelioid patients. The sarcomatoid pa-
tients, while there were some metastases, the numbers are too small
to make any dramatic conclusions from.
As far as the N1 dissection is concerned, when we have extrap-
leural patients, our pathologists do get in there and follow the bron-
chus down and get the multiple nodal stations from the N1 levels.
Our main point with this paper was we took it for granted that,
you know, you do a mediastinal nodal dissection when you do
a pleurectomy, and until we did this paper, we realized we weren’t
staging the N1 nodes at the time of pleurectomy. So now it will be
our routine to go ahead if we’re doing a pleurectomy to try and get
the level 10 nodes out, et cetera.
As far as clinically staging these patients, it’s quite difficult, as
you pointed out, where you have the pleural rind and right near
that pleural rind is a level 7 node or a level 8 or 9 node, and it’s
very difficult to tell whether you’re hitting the node or whether
you’re hitting tumor regardless of whether you’re doing it by endo-
scopic ultrasound or endobronchial ultrasound. Although I think
those roles will come into play later on down the line, it’s a difficult
problem and I don’t think we’ll be able to understand that. Right
now the best tools that we have for preoperative staging are CAT
scan and PET scan together, and that’s about it.tember 2008
